Significance and relationship between DJ-1 gene and survivin gene expression in laryngeal squamous cell carcinoma by Shen, Z. et al.
European Journal of Histochemistry 2011; volume 55:e9
[page 50] [European Journal of Histochemistry 2011; 55:e9]
Significance and relationship
between DJ-1 gene and 
survivin gene expression 
in laryngeal squamous cell 
carcinoma
Z. Shen,1,2 Y. Ren,2 D. Ye,1,2 J. Guo,2
C. Kang,2 H. Ding2,3
1Department of Otorhinolaryngology-
Head and Neck Surgery, Lihuili Hospital
of Ningbo University;
2Ningbo University School of Medicine;
3Department of Pathology, Lihuili
Hospital of Ningbo University, China
Abstract 
This study aimed at exploring the correla-
tion between DJ-1 gene and survivin gene in
laryngeal squamous cell carcinoma by analyz-
ing their gene expression levels and their rela-
tionship  with  clinicopathologic  parameters.
The expression of DJ-1 gene and survivin gene
in  82  laryngeal  carcinoma  tissues  from
patients and 82 negative surgical margin tis-
sue samples were detected by immunohisto-
chemistry,  respectively.  The  correlation  of
their expression levels and patients’ clinical
parameters  were  then  analyzed  by  Pearson
correlation  analysis.  The  positive  detection
rates of DJ-1 and survivin in laryngeal carcino-
ma  tissues  were  71.95%  and  60.98%,  which
were higher than those of the normal control
that  were  29.27%  and  0.00%,  respectively
(P<0.01). The positive detection rates of DJ-1
and survivin were found associated with tumor
stages  (P<0.05),  but  not  with  lymph  node
metastasis.  The  DJ-1  gene  expression  level
was  related  to  cell  differentiation  (P<0.05).
Finally,  a  positive  correlation  between  DJ-1
and survivin gene expression in laryngeal car-
cinoma was found. The overall survival rate of
patients was 51.2%, and disease-free survival
(DFS)  was  39.0%.  DFS  in  DJ-1  negative-
expression group was 87.0%, and 20.3% in DJ-
1  positive-expression  group.  The  negative
expression  of  DJ-1  was  associated  with  a
shorter mean patient DFS time (44.643±1.417
months), whereas positive expression of DJ-1
was associated with a longer mean DSF time
(25.943±1.297 months). DJ-1 and survivin play
a vital role in the occurrence and development
of laryngeal carcinoma. DJ-1 may promote the
carcinogenesis of laryngeal cells by up-regulat-
ing the survivin gene expression.
Introduction  
Laryngeal  carcinoma  is  a  common  malig-
nant tumor. Globally speaking, it is the second
incidence rate among head and neck cancers,
and the 11th among all human cancers.1 The
major pathological type of laryngeal cancers is
squamous cell carcinoma, accounting for 99%
of the laryngeal malignant tumors. The laryn-
geal carcinoma incidence rate has an obvious
trend  of  increase  in  recent  years,  but  the
mechanism of its occurrence and development
is still unclear. 
DJ-1 gene is a new found mitogen depend-
ence oncogene. Early study showed that the
mutation  of  DJ-1  gene  might  cause  Park  -
insonism  disease.2 Recent  studies  indicate
that DJ- 1 is closely related to the occurrence,
progress  and  prognosis  of  the  malignant
tumors.3-6
Survivin is a kind of inhibitors of apoptosis
proteins (IAPs). Because of its special biologi-
cal  structure  and  characteristics,  survivin
plays  a  vital  role  in  the  occurrence  and
progress of most malignant tumors by partici-
pating  in  inhibiting  apoptosis,  interrupting
mitosis  and  angiogenesis,  and  reducing
chemoradiation sensitivity.7-10
The functional studies of DJ-1 and survivin
on carcinogenesis have shown a possible rela-
tionship between DJ-1 and phosphatase and
tensin homolog (PTEN), a famous tumor sup-
pressor gene, as well as PTEN and survivin.11-14
However, the correlation between DJ-1 gene
and survivin gene in the laryngeal squamous
cell carcinoma (LSCC) has not been reported. 
Our previous study found that both mRNA
and protein levels of DJ-1 and survivin were
suppressed by DJ-1-small interference RNA.15
The  result  demonstrates  a  possible  linkage
between DJ-1 and survivin. To explore the clin-
ical  significance  of  DJ-1  and  survivin,  this
study compared DJ-1 and survivin expressions
in LSCC tissues and negative surgical margin
tissues  by  immunohistochemistry  and  con-
firmed their correlation in carcinogenesis. We
hope to assess the possibility of using them as
prognostic markers in LSCC, to improve laryn-
geal cancer diagnosis and provide a new theo-
retical basis for decision-making.
Materials and Methods 
Materials
A total of 82 cancer samples and 82 negative
surgical margin tissue samples was collected
from patients with LSCC who received surgery
between  2006  and  2010  at  Li  Huili  Hospital,
Ningbo, China. Informed consent was obtained
from all subjects. The Human Research Ethics
Committee  in  Li  Huili  Hospital  approved  all
aspects of the study. None of these patients had
received  prior  treatment.  The  diagnosis  was
confirmed  by  two  pathologists.  The  extent  of
tumor at the time of operation was classified
according to the tumor-node-metastasis (TNM)
staging  system  of  the  International  Union
Against Cancer. The case numbers of T1~T4
were 22，17, 27, and 16, respectively. Among
them, 54 cases had no lymph node metastasis
(N0). For clinical stages from I to IV, their num-
bers were 17, 16, 34, and 15, respectively. The
numbers of well differentiation, moderately dif-
ferentiation, and poor differentiation were 29,
36, and 17, respectively. Patients were sched-
uled  for  physical  examination,  laryn-
gofiberscopy, and chest X-ray or CT scan every
month during the first year after surgery, then
every 3 months for 2 years, and every 6 months
thereafter.  Follow-up  focused  specifically  on
recurrence (local and distant), disease-free sur-
vival  (DFS),  and  overall  survival.  There  have
been 40 patients died and 10 recurrences dur-
ing our follow-up by December 2010.
Antibodies
The  rabbit  antihuman  survivin  and  DJ-1
polyclonal antibody for immunohistochemistry
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were  purchased  from  Zhongshan  Golden
Bridge  Biotechnology  Company  (Beijing,
China)  and  Abcam  Biotechnology  Company
(Cambridge,  MA,  USA),  respectively.  Tetra  -
zolium (BCIP/NBT) alkaline phosphatase color
development  kit  was  from  Boster
Biotechnology Company (Wuhan, China).
Immunohistochemistry
The  procedures  included  follow  steps:
dewaxed  and  hydrated;  rinsed  with  water;
repaired antigens under pressure by citric acid
buffer for 2.5 min; rinsed with water; hydrogen
peroxide  solution  was  added  to  remove
endogenous  peroxidase;  incubated  at  room
temperature for 10 min; rinsed with phosphate
buffer solution (PBS); incubated with primary
antibody at 4°C over night; rinsed with PBS;
second antibody was added and incubated for
15 min; rinsed with PBS; cells were colored by
Diaminobenzidine  (DAB)  Horseradish
Peroxidase  Color  Development  Kit  (Maixin
Biotechnology Co., Fujian, China). At last, cells
were after stained by hematoxylin (Maixin). 
The assessment of positive stain for DJ-1
protein: under high power field of microscopy,
100 tumor cells were counted; and total of five
fields were investigated. According to the pos-
itive rate, the expression of DJ-1 was divided
into two groups: negative expression (positive
rate  <5%)  and  positive  expression  (positive
rate >5%).16 The assessment of positive stain
for survivin protein, the positive-cell rate and
stain degree of positive cells were divided into
different levels. The score criterion of positive
cell  rate  was:  0  (cytoplasm  without  being
dyed), 1 (1-25%), 2 (26%-50%), 3 (51-75%),
and 4 (76-100%). The score criterion for stain
degree of positive cells was: 0 (negative), 1
(weak  stain),  2  (moderate  stain),  and  3
(strong stain). If the sum of two scores was
more than 4, the expression of survivin was
considered as positive.17
Western blot analysis 
Lysates from tissue samples were prepared
using radioimmunoprecipitation (RIPA) buffer
[10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1%
NP-40,  1  mM  EDTA,  0.1%  SDS,  and  1  mM
dithiothreitol]. After centrifugation at 14,000
rpm for 15 min at 4°C, the supernatants were
collected. Proteins were resolved by SDS–poly-
acrylamide gel electrophoresis, and then trans-
ferred to polyvinylidene fluoride (PVDF) mem-
branes  (Millipore  Corporation,  Bedford,  MA,
USA). The membranes were blocked with 5%
defatted milk powder for 2 h at room tempera-
ture, then incubated with rabbit anti-human
DJ-1 antibody or anti-human survivin antibody
(Santa Cruz Biotechnology, CA, USA) at 4˚C
overnight and subsequently incubated for 1 h
with  alkaline  phosphatase  conjugated  goat
anti-rabbit antibody (Boster). The expression
of  ʲ-actin  (Sigma-Aldrich,  Saint  Louis,  MO,
USA) was used as a normalization control for
protein loading. The immunoblots were visual-
ized by use of a 5-bromo-4-chloro-3-indolylpho  -
sphate/nitroblue.
Statistical analysis
Statistical  analysis  was  performed  using
Statistical Analysis System (SAS) software 6.0
(SAS Institute Inc., Cary, NC, USA). The differ-
ence  of  DJ-1  or  survivin  positive  detection
rates between laryngeal carcinoma tissues and
normal  tissues,  and  their  relationship  with
clinical parameters were analyzed by ˇ2-test.
The correlation between DJ-1 expression and
survivin expression in laryngeal carcinoma tis-
sues  was  analyzed  by  Pearson  correlation
analysis. The correlation between the expres-
sion of different markers and patient survival
was done by Kaplan-Meier analysis. The log-
rank test was applied to test whether the corre-
lation was statistically significant. Multivariate
survival analysis was performed with the Cox
regression analysis. The level of significance
was set at P<0.05.
Results
DJ-1 and survivin expressions in
laryngeal carcinoma tissues and
normal laryngeal mucous tissues
The DJ-1 protein, which was mainly stained
in cytoplasm, was observed in cancer cells, but
not in normal cells (Figure 1). Similar to DJ-1,
survivin  protein  also  stained  in  yellowish-
brown and found in cytoplasm of cancer cells
(Figure 2). The positive detection rate of DJ-1
protein  in  laryngeal  carcinoma  tissues  was
71.95%,  while  29.27%  in  normal  laryngeal
mucous tissues (P<0.01). The survivin expres-
sion was only found in cancer tissues. The pos-
itive detection rate of survivin protein in laryn-
geal carcinoma tissues was 60.98% (P<0.01,
comparing with normal tissues).  
Relationship between DJ-1 expres-
sion or survivin expression in laryn-
geal carcinoma tissues and clinical
parameters
By analyzing the positive detection rates of
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Figure 1. Immunohistochemistry analysis
of DJ-1 protein in laryngeal carcinoma tis-
sues (A) and normal laryngeal mucous tis-
sues (B). A, high differentiated squamous
cell carcinoma. The DJ-1 protein, which
was  mainly  found  in  cytoplasm,  was
stained as yellowish-brown (×20); B, nor-
mal laryngeal mucous tissues. There was
no  DJ-1  expression  in  cytoplasm  (×40).
Scale bar: 100 µm.
Figure 2. Immunohistochemistry analysis
of survivin protein in laryngeal carcinoma
tissues (A) and normal laryngeal mucous
tissues  (B).  A,  well  differentiated  squa-
mous cell carcinoma. The survivin protein,
which was mainly fund in cytoplasm, was
stained as yellowish-brown(×20); B, nor-
mal laryngeal mucous tissue. There was no
survivin  expression  in  cytoplasm(×20).
Scale bar: 100 µm.[page 52] [European Journal of Histochemistry 2011; 55:e9]
DJ-1 protein and survivin protein, we found
that the positive detection rates of DJ-1 and
survivin  expression  were  associated  with
tumor  stages  (P<0.05),  but  not  with  lymph
node  metastasis  (Table  1).  DJ-1  expression,
but not survivin expression, was related to cell
differentiation (P<0.05, Table 2).
Correlation of DJ-1 expression and
survivin expression in laryngeal
cancer tissues
Among  82  laryngeal  cancer  cases,  44  were
both DJ-1 and survivin positive expressed, and 17
both negative expressed (Table 3). Pearson cor-
relation analysis indicated that a positively corre-
lation between DJ-1 and survivin expression in
laryngeal carcinoma was found (r=0.4079).
Western blot analysis of DJ-1 and
survivin
As shown in Figure 3, compared with nega-
tive surgical margin tissue samples, increased
DJ-1  and  survivin  expression  in  LSCC  were
detected  by  Western  blot.  Survivin  did  not
expressed in negative surgical margin tissue.
Their  over  expression  was  associated  with
poorer  cell  differentiation,  higher  pTNM
pathologic staging and T staging. 
Survival analysis
The overall survival rate of 82 patients was
51.2%, and DFS was 39.0%. Using univariate
Kaplan-Meier  survival  estimation  with  log-
rank comparison, we found that DFS in DJ-1
negative-expression  group  was  87.0%,  and
20.3% in DJ-1 positive-expression group. The
negative  expression  of  DJ-1  was  associated
with  a  shorter  mean  patient  DFS  time
(44.643±1.417  months),  whereas  positive
expression  of  DJ-1  was  associated  with  a
longer mean DSF time (25.943±1.297 months;
Figure  4).  And  DFS  was  correlated  with  T
stage, pTNM pathologic staging, N stage, and
degree  of  tumor  differentiation  (P<0.05).
Multivariate survival analysis was performed
with  the  Cox  proportional  hazards  model.  It
showed that only pTNM pathologic staging, DJ-
1 and survivin expressions were independent
predictor  for  LSCC  patient  survival  (P<0.05;
hazard ratio: 4.087, 15.817 and 5.111, respec-
tively); while T stage, N stage and degree of
tumor differentiation were not (P>0.05). 
The relationship between overall survival
and DJ-1 expression, survivin expression and
clinicopathologic variables is shown in Table
4.  Just  like  the  DFS,  only  DJ-1  expression,
survivin  expression  and  pTNM  pathologic
staging  were  the  predictor  parameter  for
overall  survival.  We  also  analyzed  the  sub-
group according to DJ-1/surviving expression,
and  found  that  DJ-1+/surviving+  subgroup
had  the  poorest  prognosis,  while  the  DJ-1-
/survivin-  subgroup  had  the  best  prognosis
(Figure 5 and Table 4).
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Table 1. Relationship between DJ-1 or survivin expressions and clinical parameters.
Group n DJ-1 Survinvin
+-Positive  ˇ2 P+ - Positive  ˇ2 P
rate (%) rate (%)
T stage
T1 /T2 39 23 16 58.97 6.2058 0.0127 18 21 46.15 6.8662 0.0088
T3/T4 43 36 7 83.72 32 11 74.42
Lymph node metastasis
N0 54 39 15 72.22 0.0058 0.9395 35 19 64.81 0.9796 0.3223
N1 28 20 8 71.43 15 13 53.57
Clinical stage
I / II 33 19 14 57.58 5.6549 0.0174 15 18 45.45 5.5909 0.0181
III / IV 49 40 9 77.55 35 14 71.43
Table 2. Relationship between DJ-1 or survivin expressions and pathologic differentia-
tion.
Group n DJ-1 Survinvin
+- Positive  ˇ2 P+ - Positive  ˇ2 P
rate (%) rate (%)
Well-
differentiated 29 16 13 55.17 6.25900.0124 13 16 44.83 4.9168 0.0266
Moderate, 53 43 10 81.13 37 16 69.81
poor 
differentiated
Figure 3. Western blot results of DJ-1 and
survivin expression.
Figure 4. Kaplan-Meier analysis of the sig-
nificance of DJ-1 and survivin expression
and  clinicopathologic  parameters  in  pre-
dicting  patient  survival.  A,  disease-free-
survival  curve  between  different  DJ-1
expressions. B, disease-free-survival curve
between different survivin expressions.[European Journal of Histochemistry 2011; 55:e9] [page 53]
Discussions
Studies have shown that the occurrence and
development  of  malignant  tumor  are  closely
related to the over expression of some onco-
genes  and  apoptosis  inhibitory  factors.  As  a
mitogen  dependent  oncogene,  DJ-1  has
become a research focus in the last years. A
proteomics  testing  found  that  breast  cancer
cell lines SUM-44 secreted DJ-1 protein and
that the DJ-1 expression and its antibodies in
breast cancer were more than those in non-
cancer cases. The measurement of DJ-1 anti-
bodies in peripheral blood was thought be a
useful marker of detection the occurrence and
development of breast cancer.5 MacKeigan et
al.6 reported  that  in  primary  lung  cancer
patients, the recurrence rate of patients with
high-level of DJ-1 obviously was higher than
that with low-level of DJ-1. DJ-1 in cervical tis-
sues  was  obviously  increased  and  might  be
used as a cervical cancer progression marker.18
A  positive  relationship  of  DJ-1  with  tumor
invasion and metastasis was found in hepato-
cellular carcinoma, and DJ-1 was also  high-
lighting  an  important  role  in  chemoresis-
tance.19Landon et al.20identified several ligand
binding  hot  spots  for  DJ-1,  and  one  in  the
dimer interface might be bound with pharma-
cological chaperone. These hot spots were con-
sidered providing novel starting points for drug
discovery  efforts.  Considering  its  effect  in
oncogenesis, the roles of DJ-1 in the occur-
rence, development and prognosis of laryngeal
cancer need to be cleared. 
In this study, we found that DJ-1 expression
level in laryngeal cancer tissues was signifi-
cantly  higher  than  that  in  normal  mucosa
(Figure  1).  Its  positive  detection  rates  were
associated with tumor stages and cell differen-
tiation  (Table  1-2).  The  high  level  of  DJ-1
expression  might  indicate  worse  T  stage,
pTNM pathologic stage and differentiation. In
Western blot analysis, this tendency could be
presented  as  well.  Contradictory  to  previous
studies,  there  was  no  significant  difference
between DJ-1 expression of groups with and
without lymph node metastasis. So we did not
find the evidence of the role of DJ-1 in LSCC
metastasis. Concerning survival, DJ-1 positive
expression  significantly  affected  the  overall
survival and DFS of patients with LSCC, and it
served as an independent predictor related to
DFS after surgery for laryngeal cancer. These
results indicate that DJ-1 may play an impor-
tant role in the development of laryngeal can-
cer, and a potential prognostic parameter for
LSCC.
As the strongest apoptosis inhibitory factor,
survivin was involved in the regulation of cel-
lular  proliferation  and  angiogenesis  in  can-
cer.21 Wang  et  al.22 found  that  survivin
expressed in laryngeal squamous cell carcino-
ma, but did not express in normal laryngeal
mucous tissue. In our study, survivin was also
found highly expressed in laryngeal cancer. In
addition, the Western blot analysis confirmed
the result. The level of its expression was asso-
ciated with several clinicopathologic parame-
ters (Figure 2; Table 1); high level might pre-
dict worse prognosis as an independent predic-
tor (Figure 4). All result implied that survivin
was a useful prognostic marker for LSCC.
In  our  previous  study,  we  found  that  the
expression levels of these two genes in laryn-
geal cancer Hep-2 cells were consistent.15 In
this  study,  this  linkage  was  studied  using
laryngeal cancer tissues. The results showed
that the DJ-1 gene expression was positively
correlated  to  the  survivin  gene  expression
(Table  3).  The  same  phenomenon  has  been
found in breast,5 cervical18 and liver cancer.23
Studies have shown that DJ-1 is a regulatory of
PTEN,  a  recognized  tumor  suppressor  gene,
which promotes the PI3K/Akt/mTOR pathways
so as to cause the constant proliferation and
growth  of  cells.3,4 Recently,  Sitaram  et  al.24
found that DJ-1 gene regulated the expression
of  PTEN  through  PI3K-AKT/PKB  pathways.
Survivin expression is negatively correlated to
PTEN  expression  in  cancers.  Carter  et  al.11
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Table 4. Univariate and multivariate analysis of overall survival.
Clinicopathologic  Univariate analysis Multivariate analysis
variables Means of survival time ˇ2 P Risk ratio（95% CI） P
DJ-1 expression 
Negative 45.952±0.705 24.746 0.001 22.248 0.001
Positive 28.656±1.622 （3.266-142.820）
Surviving expression 
Negative 44.125±1.204 33.466 0.001 8.925 ＜0.001
Positive 25.977±1.493 (2.715-29.343）
T stage
T1/T2 41.462±1.670 28.764 0.001
T3/T4 24.922±1.293
N stage
N0 37.246±1.707 9.327 0.002
N1 26.908±2.137
pTNM stage
I / II 45.606±0.959 50.887 0.001 10.862（1.943-60.732） 0.007
III / IV 4.234±1.127
Differentiation
Well 41.671±1.662 12.778 0.001
Moderate/poor 28.367±1.621
pTNM, pathological tumor-node-metastasis.
Table 5. Analysis of survival among DJ-1/survivin subgroups.
Subgroups n Survival rate  ˇ2 P
DJ-1+/survivin+ 44 20.5% 46.506 0.000
DJ-1+/survivin– 15 33.3%
DJ-1–/survivin+ 6 50.0%
DJ-1–/survivin– 17 88.2%
Table  3.  Correlation  of  DJ-1  expression
and survivin expression in laryngeal cancer
tissues.
Survivin DJ-1
+-
+ 44 6
- 15 17
Figure 5. Survival curves of the subgroups
analyzed by Kaplan-Merier analysis.[page 54] [European Journal of Histochemistry 2011; 55:e9]
found that the PI3K signal transduction path-
way regulated survivin on both mRNA level and
protein  level.  Under  normal  circumstances,
PTEN  inhibits  survivin  expression  through
PI3K/AKT pathways. When PTEN activity gets
lost, the expression of survivin will increase
and then promote cell proliferation and inhibit
apoptosis.12 A further study showed that PTEN
also  stimulated  P21  expression  and  then
increased the expression of survivin.13 We pre-
sume therefore that there are some regulation
mechanisms between DJ-1 and survivin that
function through PI3K/Akt/mTOR pathways. 
In  the  subgroups  study,  we  found  that
patients with DJ-1+/survivin+ had the poorest
prognosis  than  other  groups,  while  patients
with  DJ-1-/survivin-  may  indicate  a  better
prognosis  and  longer  survival  (Table  5).
Although a lot of researches advocating DJ-1 or
survivin as potential biomarkers already have
been  performed,  oncogenesis  is  a  complex
process involving multiple oncogenes and sig-
nal  pathways;  the  combination  use  of  onco-
genes as cancer marker may be more persua-
sive than the use of single molecular marker.
Our results indicate that combination of DJ-1
and survivin may be better biomarker for prog-
nosis of laryngeal cancer.
Conclusions 
Considered all together, our findings show
that DJ-1 may regulate survivin expression as
an upstream gene and the expressions of two
genes are closely related to clinicopathologic
parameters of laryngeal cancer. By Cox regres-
sion analysis, both of them are independent
prognostic predictors for DFS of laryngeal can-
cer. DJ-1 and survivin could be used as poten-
tial biomarker for LSCC progression and prog-
nosis.
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